The new Eurosurveillance website is almost here.

Eurosurveillance is on the updated list of the Directory of Open Access Journals and in the SHERPA/RoMEO database. Read more here.

On 6 June 2017, the World Health Organization (WHO) published updates to its ‘Essential Medicines List’ (EML). Read more here.

Follow Eurosurveillance on Twitter: @Eurosurveillanc

In this issue

Home Eurosurveillance Edition  2017: Volume 22/ Issue 25 Article 4
Back to Table of Contents
Previous Download (pdf)

Eurosurveillance, Volume 22, Issue 25, 22 June 2017
Research article
Gadroen, Kemmeren, Bruijning-Verhagen, Straus, Weibel, de Melker, and Sturkenboom: Baseline incidence of intussusception in early childhood before rotavirus vaccine introduction, the Netherlands, January 2008 to December 2012

+ Author affiliations

Citation style for this article: Gadroen K, Kemmeren JM, Bruijning-Verhagen PC, Straus SM, Weibel D, de Melker HE, Sturkenboom MC. Baseline incidence of intussusception in early childhood before rotavirus vaccine introduction, the Netherlands, January 2008 to December 2012. Euro Surveill. 2017;22(25):pii=30556. DOI:

Received:19 June 2016; Accepted:17 November 2016


Rotavirus infections are a leading cause of severe diarrhoeal illness in infants and young children [1]. As demonstrated by a number of studies, rotavirus vaccines are effective in preventing severe diarrhoeal illness caused by certain rotavirus serotypes [2,3]. In 1999 however, the first rotavirus vaccine, RotaShield (Wyeth Laboratories, Inc., Pennsylvania, United States), was voluntarily withdrawn from the market due to an unexpected association with intussusception [4]. Intussusception is a serious condition that can be described as the invagination of a proximal segment of the bowel into the distal bowel. If left untreated, the blood flow can become compromised, leading to bowel infarction and perforation. In 2006, two second generation rotavirus vaccines, Rotarix (GlaxoSmithKline Biologicals, Rixensart, Belgium) and RotaTeq (MSD vaccines, Lyon, France), were approved for marketing in Europe. In 2009, the World Health Organization Strategic Advisory Group of Experts (SAGE) recommended the use of rotavirus vaccines in all national immunisation programs, and by 2016, 11 countries of the European Union had included rotavirus vaccination in their national vaccination programme [5]. Although large-scale pre-licensure clinical trials did not identify an increased risk for intussusception, post-licensure data suggested a small increase in risk of intussusception that was closely linked to the age of vaccination after rotavirus vaccination with both licensed vaccines [6-11].

The aetiology of primary intussusception in young children remains unclear. Intussusception is most common between 5 and 7 months of age [12]. Approximately 60% to 75% of children diagnosed with intussusception are younger than 1 year of age, and approximately 80% to 90% are younger than 2 years of age. Most episodes occur in otherwise healthy children with a male to female predominance of ca 3:2 [13].

Ultrasonography is the method of choice to detect intussusception. Ultrasound-guided reduction using hydrostatic or pneumatic pressure by enema is the treatment of choice. Surgical treatment is indicated when ultrasound-guided reduction is incomplete or in case perforation is suspected.

Sentiments towards the importance of vaccination in general are positive overall but confidence in vaccine safety is less positive, particularly in the European region [14]. In the Netherlands, where the impact of rotavirus vaccine is considered modest [15], concerns about vaccine safety may lead to vaccine hesitancy and decreased vaccination coverage for vaccine-preventable diseases in general [16]. Knowledge of the background incidence rates of possible adverse events is a crucial part of assessing possible vaccine safety concerns. It allows for a rapid observed vs expected analysis and helps to distinguish legitimate safety concerns from events that are temporally associated with but not necessarily caused by vaccination [17]. In the case of rotavirus vaccination, it is important to know the background incidence of intussusception. Studies in Europe have reported incidence rates of intussusception between 24.2 and 60.4 per 100,000 person-years [18-23] and show a decline over time [19,22]. Methods used to estimate these incidence rates differ in age of source population, length of study period, and detection and validation of cases.

To date, the use of rotavirus vaccines in the Dutch population can be considered negligible. Rotavirus vaccines are not included in the Dutch national vaccination programme, are not recommended for routine use and are not reimbursed by the health insurance. To support future rotavirus vaccine safety surveillance in the event that rotavirus vaccine would be introduced in the Dutch national vaccination programme, this study aims to calculate the baseline incidence rates of intussusception in the Netherlands.


Data sources

For this study two different data sources that capture a partially overlapping source population were used: an administrative hospital discharge database and a primary healthcare database. Administrative hospital discharge data were obtained from the Dutch hospital register, Landelijke Basisregistratie Ziekenhuiszorg (LBZ). Hospitals and university medical centres in the Netherlands have a legal and statutory obligation to collect and provide electronic administrative data to the LBZ database on a monthly basis. The LBZ database covers more than 80% of the total Dutch population of 17 million people. It contains anonymised data on hospital admissions, outpatient consultation and emergency department visits including medical diagnoses, as well as patient-specific data such as age and sex [24]. Coding of discharge diagnoses is performed by participating hospitals according to the International Classification of Diseases, Ninth Revision (ICD-9) [25]. A validation study showed high accuracy of coding and concluded that the discharge data are generally of high quality [26].

The second source was a primary healthcare database, the Integrated Primary Care Information (IPCI) database. IPCI is a longitudinal observational database created specifically for pharmaco-epidemiological studies [27]. It contains anonymised data, including notes from computer-based medical records of around 600 general practitioners (GPs) located in the Netherlands. IPCI contains information on more than 1.1 million patients from over 200 participating GP practices. The age and sex distribution of the population is representative for the Netherlands. In the Dutch healthcare system, the GP acts as a gatekeeper for all medical care. It is estimated that more than 75% of the Dutch population in the age group 0–3 years will visit their GP at least once per year [28]. In the event intussusception is suspected, the patient will be referred to hospital for confirmation and treatment. Following consultation at the hospital, it is standard practice to forward the details of the consultation and the outcome to the GP. In the rare event a patient by-passes the GP, the hospital will also forward the details of the consultation and the outcome to the patient’s GP. Therefore, patients’ medical records at GP practices are likely to contain all relevant medical information.

Study design and population

Cases were retrieved differently from the two data sources. From the LBZ hospital discharge database, all cases with a primary or secondary discharge diagnosis of intussusception (ICD-9 CM code 560.0) in children aged between 0 and 36 months (i.e. children aged 0–35 months) at admission were retrieved for the period from 1 January 2008 to 31 December 2012. Cases with a secondary diagnosis of intussusception were reviewed by a paediatrician to determine whether the combined set of ICD codes for the admission was compatible with a new occurrence of intussusception, taking comorbidities, patient age and primary discharge diagnosis into account. Possible duplicate reports because of patient transfers were identified based on sex, birthdate and date of diagnosis, and were excluded.

Based on the data captured by IPCI, we constructed a dynamic cohort. Initially, we attempted to assess the incidence rate over a period of 10 years, from 1 January 2003 to 31 December 2012. However, the addition of many new practices to the IPCI database in 2007 caused the observation time to vary considerably over the course of the 10-year study period and we subsequently restricted the analysis to a period of 5 years, from 1 January 2008 to 31 December 2012. This yielded a more stable population (Table 1).

Table 1

Incidence rate of intussusception per 100,000 person-years based on validated cases from the Integrated Primary Care Information (IPCI) database, the Netherlands, January 2003–December 2012

Year    Cases   
Person time
Incidence rate per 100,000 person-years 95% CI
2003 0 2,226 NA NA
2004 1 2,323 43.0 3.9–200.7
2005 0 4,549 NA NA
2006 0 978 NA NA
2007 0 1,495 NA NA
2008 2 4,045 49.4 9.9–158.5
2009 2 8,435 23.7 4.7–76.0
2010 4 14,087 28.4 9.5–67.5
2011 2 19,326 10.3 2.1–33.2
2012 5 24,649 20.3 7.7–44.5

We only selected children who were born during the study period and who had contributed longitudinal data to the IPCI database from birth onwards. Follow-up started from birth and continued until the date the patient became a case, the patient reached the age of 36 months, the patient died, the patient was transferred out of the GP’s practice, the date of last data collection from the general practice or the end of the study period was reached, whichever date came first. In the IPCI database, cases were identified by automated scanning of keywords in GPs’ notes in the medical records. The complete medical records of all potential cases were reviewed by a medical doctor for details alluding to additional diagnostic procedures or received treatment. An identified case was considered a true case if the medical journal of that particular patient contained results from ultrasound examination confirming the diagnosis and/or details regarding receiving treatment specific for intussusception such hydrostatic reduction. Cases with an actual diagnosis of intussusception were subsequently classified by level of evidence using the web-based Automated Brighton Collaboration Case definition tool (ABC-tool) for intussusception. Level one corresponds to the highest level of diagnostic evidence and level three corresponds to the lowest [29]. We subsequently compared LBZ and IPCI data for those years where comparable data were available.


Age-specific incidence rates were calculated from data in each of the two data sources using the number of intussusception cases from that source as a numerator and the study population as denominator. Since dominator data are not available in the LBZ database, approximate denominators based on national population data from Statistics Netherlands (CBS) were used, assuming that 80% of the population would be covered in the LBZ database [30]. In the IPCI database, the underlying study cohort could be well defined in terms of the number of person-years of follow-up of patients. Incidence rates of intussusception were calculated by dividing the number of incident intussusception cases by the total number of person-years. Incidence rates were calculated by calendar year, age category and sex. Confidence intervals (95% CI) for each estimate were based on the Poisson distribution.


Landelijke Basisregistratie Ziekenhuiszorg (LBZ) database

In the LBZ database, 705 potential cases of intussusception were identified during the study period and 166 duplicate cases were excluded. Based on the remaining 539 identified cases of intussusception, the overall crude incidence rate over the study period from 1 January 2008 to 31 December 2012 was 22.6 per 100,000 person-years (95% confidence interval (CI): 20.9–24.4). Figure 1 shows the age-specific incidence rates; the highest rate was observed in children < 12 months of age.

Figure 1

Intussusception incidence rate in children < 36 months of age per 100,000 person-years by age and data source, the Netherlands, 1 January 2008–31 December 2012


IPCI: Integrated Primary Care Information database; LBZ: Landelijke Basisregistratie Ziekenhuiszorg database.

Vertical lines represent the 95% confidence intervals.

The incidence rate remained constant over time (Figure 2).

Figure 2

Intussusception incidence rate in children < 36 months of age per 100,000 person-years by year and data source, the Netherlands, 1 January 2008–31 December 2012


IPCI: Integrated Primary Care Information database; LBZ: Landelijke Basisregistratie Ziekenhuiszorg database.

Shaded areas represent the 95% confidence intervals.

The incidence rate in children < 12 months of age varies considerably by age, but as is expected, the data show that is it more common after the age of three months (Figure 3).

Figure 3

Intussusception incidence rate in children < 12 months of age per 100,000 person-years by age category and year based on non-validated cases from the LBZ database, the Netherlands, 1 January 2008–31 December 2012


LBZ: Landelijke Basisregistratie Ziekenhuiszorg.

The LBZ database contains administrative hospital data.

Vertical lines represent the 95% confidence intervals.

Integrated Primary Care Information (IPCI) database

From the IPCI database, 155,880 children were included in the initial study cohort (Table 2). Within this population, 131 potential cases were detected after a sensitive search for indicators of intussusception in narratives. We subsequently restricted age-specific analysis to the period from 1 January 2008 to 31 December 2012, which yielded a more stable population. In the period from 1 January 2008 to 31 December 2012, the population comprised of 144,617 children. Following manual validation by a medical doctor, 15 cases (14 definite, 1 possible) were classified as incident intussusception (Table 1). When using the ABC-tool, all cases were classified as having insufficient information to meet the Brighton Collaboration case definition of intussusception. This was because none of the cases included any information regarding one of the exclusion criteria: absence of surgical evidence for an alternative diagnosis. Based on the number of cases validated by a medical doctor, the crude incidence during the period 1 January 2008 to 31 December 2012 was 21.2 per 100,000 person-years (95% CI: 12.5–34.3). The incidence was higher in boys than in girls, and was highest in the lowest age category, subsequently decreasing with age (Table 3). Results per age category are provided in Figure 1, and overall incidence per calendar year in Figure 2.


Study cohort details for investigation of intussusception incidence rates using the IPCI database, the Netherlands, 1 January 2008–31 December 2012

Study cohort Time period
1 Jan 2003–31 Dec 2012 1 Jan 2008–31 Dec 2012
Study population (n) 155,880 144,617
Person time of follow up (person-years) 82,113 70,542
Number of intussusception cases (n) 16 15

IPCI: Integrated Primary Care Information.

The IPCI database contains general practitioner medical records.

Table 3

Intussusception incidence rates in children < 36 months of age per 100,000 person-years based on validated cases from the IPCI database, the Netherlands, January 2003–December 2012

Sex and age Time period
1 Jan 2003–31 Dec 2012 1 Jan 2008–31 Dec 2012
Incidence rate per 100,000 person-years 95% CI Incidence rate per 100,000 person-years 95% CI
Overall 20.2 12–32 21.3 12.5–34.3
Male 26.7 14.2–46.2 27.7 14.2–49.2
Female 12.7 4.8–27.9 14.6 5.5–32
0–11 months 24.6 12.6–43.7 27.9 14.3–49.5
12–23 months 19.8 7.5–43.3 18 6.0–42.9
24–35 months 6.9 0.6–32 8.1 0.7–37.9

IPCI: Integrated Primary Care Information.

The IPCI database contains general practitioner medical records.


This study showed that background incidence rates of intussusception can be estimated using routinely collected healthcare data. The intussusception incidence rate in children < 12 months of age is 27.9 per 100,000 person-years (95% CI: 14.3–49.5) based on cases from the primary healthcare data that were validated, and 35.0 per 100,000 person-years (95% CI: 31.3–39.0) based on the non-validated hospital data. These estimates are on the lower end of published incidences across Europe. Consistent with previous research [19,22,23,31], the incidence rate in boys was higher than in girls, and was highest in the youngest age group.

When comparing the intussusception incidence rates derived from the IPCI primary healthcare database with those derived from the LBZ hospital database, the results from the IPCI database are validated but less precise, and possibly an underestimation. From the hospital database, we were able to derive precise incidence rates for smaller age categories. However, the coding could not be validated and the incidence rate may possibly be an overestimation. A declining trend over time was not evident. The true intussusception rate is likely to be in between the estimates derived from the primary healthcare database and the hospital database. The advantage of this dual approach is that interpreting the occurrence of future cases after vaccination may be done with or without validation, and we have provided an assessment of the impact thereof.

The advantage of using a primary healthcare, GP-based database such as the IPCI was that case detection did not depend on the validity of coding as free text keyword searches, rather than codes, were used. The availability of medical notes in free text provided a rich source of information, enabling case ascertainment. Although it would be interesting to know the composition of the participating practices, we were not able to identify any evidence that would suggest that the composition of the GP practice is a risk factor for intussusception. Therefore, we consider it unlikely that our estimate is biased by the composition of the GP practices. As a denominator, we were able to use accrued time since birth. However, intussusception is a condition typically diagnosed in a hospital setting. Although it is considered standard practice to forward all relevant hospital patient data to the GP, it cannot be ruled out that some hospital diagnoses were not communicated to GPs or were substantially delayed in terms of being reported back. Since the number of ascertained cases was small, we could only calculate the incidence for age categories of one year and the confidence intervals are rather large.

The majority of first-time rotavirus infections usually occur in infancy. In high income countries, 65% occurs in infants < 1 year of age [32]. Therefore, it is recommended that rotavirus vaccination be administered before the age of 6 months. However, the reported incidence of intussusception varies substantially by age during the first 6 months of life [23,33]. Age-specific incidence rates in months or even weeks of age would be very useful in terms of informing rotavirus vaccine safety policy; however, this would require a much larger cohort.

Because the administrative hospital database covers a larger population than the primary healthcare one, we were able to derive more precise incidence rates and incidence rates for smaller age categories. Incidence rates for small age categories is particular valuable information in the context of rotavirus vaccine safety surveillance since studies suggest that the risk of intussusception caused by rotavirus vaccine is primarily in the first week after the first dose, administered in early childhood [6-11]. However, denominator data are not readily available and approximate denominators from population census data have to be used. In addition, case detection in this particular hospital database depends on the accuracy of coding and could not be validated. Published positive predictive values of ICD-9 codes for intussusception range from 75% to 81%, and are even lower when including outpatient department data [34-36]. Therefore, the hospital database estimates may be an overestimation of the true incidence. Moreover, in contrast to the primary healthcare database, the intussusception cases derived from the hospital database may contain cases of transient intussusception, recurrent intussusception and/or suspected intussusception. In order to further investigate the quality of the estimates derived from the LBZ database, a validation study could be considered. In the future, if hospital data are to be used for intussusception surveillance, distinguishing suspected intussusception cases and transient intussusception cases from true intussusception cases might be of added value.

Conflict of interest

The views expressed in this article are the personal views of the authors and may not be understood or quoted as being made on behalf of, or reflecting the position of, the Dutch Medicine Evaluation Board.

All authors confirm that there are no known conflicts of interest associated with this publication, and that there has been no financial support for this work that could have influenced its outcome.

Authors’ contributions

KG acquired the IPCI data, conducted the analysis, interpreted the study findings and drafted the manuscript. JK and PBV acquired the LBZ data, conducted part of the analysis, contributed to the interpretation of the study's findings and provided revisions to the manuscript. SS and DW provided study supervision and input to the manuscript. HM and MS provided study supervision, contributed to the interpretation of the study's findings and provided critical revisions to the manuscript.


  1. Walker CL, Rudan I, Liu L, Nair H, Theodoratou E, Bhutta ZA,  et al.  Global burden of childhood pneumonia and diarrhoea. Lancet. 2013;381(9875):1405-16. DOI: 10.1016/S0140-6736(13)60222-6 PMID: 23582727

  2. Annex I Summary Product Characteristics. Rotarix. [Accessed 20 Jun 2017]. Available from:

  3. Annex I Summary of Product Characteristics. RotaTeq. [Accessed 20 Jun 2017]. Available from:

  4. Centers for Disease Control and Prevention (CDC). Withdrawal of rotavirus vaccine recommendation.MMWR Morb Mortal Wkly Rep. 1999;48(43):1007.PMID: 10577495

  5. European Centre for Disease Prevention and Control (ECDC). Vaccine schedule: Recommended immunisations for rotavirus infection. Stockholm: ECDC. [Accessed 6 May 2016]. Available from:

  6. Buttery JP, Danchin MH, Lee KJ, Carlin JB, McIntyre PB, Elliott EJ,  et al.  Intussusception following rotavirus vaccine administration: post-marketing surveillance in the National Immunization Program in Australia. Vaccine. 2011;29(16):3061-6. DOI: 10.1016/j.vaccine.2011.01.088 PMID: 21316503

  7. Patel MM, López-Collada VR, Bulhões MM, De Oliveira LH, Bautista Márquez A, Flannery B,  et al.  Intussusception risk and health benefits of rotavirus vaccination in Mexico and Brazil. N Engl J Med. 2011;364(24):2283-92. DOI: 10.1056/NEJMoa1012952 PMID: 21675888

  8. Haber P, Patel M, Pan Y, Baggs J, Haber M, Museru O,  et al.  Intussusception after rotavirus vaccines reported to US VAERS, 2006-2012. Pediatrics. 2013;131(6):1042-9. DOI: 10.1542/peds.2012-2554 PMID: 23669521

  9. Shui IM, Baggs J, Patel M, Parashar UD, Rett M, Belongia EA,  et al.  Risk of intussusception following administration of a pentavalent rotavirus vaccine in US infants. JAMA. 2012;307(6):598-604. DOI: 10.1001/jama.2012.97 PMID: 22318281

  10. Yih WK, Lieu TA, Kulldorff M, Martin D, McMahill-Walraven CN, Platt R,  et al.  Intussusception risk after rotavirus vaccination in U.S. infants. N Engl J Med. 2014;370(6):503-12. DOI: 10.1056/NEJMoa1303164 PMID: 24422676

  11. Weintraub ES, Baggs J, Duffy J, Vellozzi C, Belongia EA, Irving S,  et al.  Risk of intussusception after monovalent rotavirus vaccination. N Engl J Med. 2014;370(6):513-9. DOI: 10.1056/NEJMoa1311738 PMID: 24422678

  12. Jiang J, Jiang B, Parashar U, Nguyen T, Bines J, Patel MM. Childhood intussusception: a literature review.PLoS One. 2013;8(7):e68482. DOI: 10.1371/journal.pone.0068482 PMID: 23894308

  13. Mandeville K, Chien M, Willyerd FA, Mandell G, Hostetler MA, Bulloch B. Intussusception: clinical presentations and imaging characteristics.Pediatr Emerg Care. 2012;28(9):842-4. DOI: 10.1097/PEC.0b013e318267a75e PMID: 22929138

  14. Larson HJ, de Figueiredo A, Xiahong Z, Schulz WS, Verger P, Johnston IG,  et al.  The State of Vaccine Confidence 2016: Global Insights Through a 67-Country Survey. EBioMedicine. 2016;12:295-301. DOI: 10.1016/j.ebiom.2016.08.042 PMID: 27658738

  15. Toenders WGM. CFH-rapport 07/33 rotavirusvaccin (Rotarix). [CFH-report 07/33 rotavirus vaccine (Rotarix)]. Diemen: College voor zorgverzekeringen; 2007. [Accessed 5 May 2016]. Dutch. Available from:

  16. World Health Organization (WHO). Summary WHO SAGE conclusions and recommendations on vaccine hesitancy. Geneva: WHO; Jan 2015. [Accessed 19 Jun 2016]. Available from:

  17. Black S, Eskola J, Siegrist CA, Halsey N, Macdonald N, Law B,  et al.  Importance of background rates of disease in assessment of vaccine safety during mass immunisation with pandemic H1N1 influenza vaccines. Lancet. 2009;374(9707):2115-22. DOI: 10.1016/S0140-6736(09)61877-8 PMID: 19880172

  18. Buettcher M, Baer G, Bonhoeffer J, Schaad UB, Heininger U. Three-year surveillance of intussusception in children in Switzerland.Pediatrics. 2007;120(3):473-80. DOI: 10.1542/peds.2007-0035 PMID: 17766518

  19. Fischer TK, Bihrmann K, Perch M, Koch A, Wohlfahrt J, Kåre M,  et al.  Intussusception in early childhood: a cohort study of 1.7 million children. Pediatrics. 2004;114(3):782-5. DOI: 10.1542/peds.2004-0390 PMID: 15342854

  20. Jenke AC, Klaassen-Mielke R, Zilbauer M, Heininger U, Trampisch H, Wirth S. Intussusception: incidence and treatment-insights from the nationwide German surveillance.J Pediatr Gastroenterol Nutr. 2011;52(4):446-51. DOI: 10.1097/MPG.0b013e31820e1bec PMID: 21415671

  21. Kohl LJ, Streng A, Grote V, Koletzko S, Liese JG. Intussusception-associated hospitalisations in southern Germany.Eur J Pediatr. 2010;169(12):1487-93. DOI: 10.1007/s00431-010-1248-x PMID: 20640443

  22. Samad L, Cortina-Borja M, Bashir HE, Sutcliffe AG, Marven S, Cameron JC,  et al.  Intussusception incidence among infants in the UK and Republic of Ireland: a pre-rotavirus vaccine prospective surveillance study. Vaccine. 2013;31(38):4098-102. DOI: 10.1016/j.vaccine.2013.06.084 PMID: 23871447

  23. Weiß S, Streng A, Kries R, Liese J, Wirth S, Jenke AC. Incidence of intussusception in early infancy: a capture-recapture estimate for Germany.Klin Padiatr. 2011;223(7):419-23. DOI: 10.1055/s-0031-1279735 PMID: 21698555

  24. Dutch Hospital Data (DHD). Dataverzameling LBZ. [Data collection LBZ]. Utrecht: DHD. [Accessed 3 Mar 2016]. Dutch. Available from:

  25. Slobbe LCJ, de Bruin A, Westert GP, Kardaun JWPF, Verweij GCG. RIVM rapport 260201002/2004: Indeling van diagnosen en verrichtingen en toepassing in nieuwe statistieken over ziekenhuisopnamen. [RIVM report 260201002/2004: Classification of diagnoses and interventions and applications of new hospital admission statistics]. Bilthoven: National Institute for Public Health and the Environment (RIVM). [Accessed 18 Jun 2017]. Dutch. Available from:

  26. Paas GRA, Veenhuizen KCW. Onderzoek naar de betrouwbaarheid van de Landelijke Medische Registratie (LMR). [Research on the reliability of the National Medical Registration (LMR)]. Utrecht: Prismant; 2002. Dutch. Available from:

  27. Vlug AE, van der Lei J, Mosseveld BM, van Wijk MA, van der Linden PD, Sturkenboom MC,  et al.  Postmarketing surveillance based on electronic patient records: the IPCI project. Methods Inf Med. 1999;38(4-5):339-44.PMID: 10805025

  28. Hupkens C, Swinkels H. Around three-quarters of population see GP and dentist once a year. The Hague: Statistics Netherlands (CBS); 3 May 2013. Available from:

  29. Bines JE, Kohl KS, Forster J, Zanardi LR, Davis RL, Hansen J,  et al. , Brighton Collaboration Intussusception Working Group. Acute intussusception in infants and children as an adverse event following immunization: case definition and guidelines of data collection, analysis, and presentation.Vaccine. 2004;22(5-6):569-74. DOI: 10.1016/j.vaccine.2003.09.016 PMID: 14741146

  30. Statistics Netherlands (CBS). Bevolking; geslacht, leeftijd en burgerlijke staat, 1 januari. [Population; gender, age and marital status, 1 January]. The Hague: CBS. [Accessed 11 Nov 2016]. Dutch. Available from:,G3&STB=G1,G2&VW=T

  31. Palupi-Baroto R, Lee KJ, Carlin JB, Bines JE. Intussusception in Australia: epidemiology prior to the introduction of rotavirus vaccine.Aust N Z J Public Health. 2015;39(1):11-4. DOI: 10.1111/1753-6405.12297 PMID: 25558780

  32. Sanderson C, Clark A, Taylor D, Bolanos B. Global review of rotavirus morbidity and mortality data by age and region. London: London School of Hygiene & Tropical Medicine; 2011.

  33. Tate JE, Steele AD, Bines JE, Zuber PL, Parashar UD. Research priorities regarding rotavirus vaccine and intussusception: a meeting summary.Vaccine. 2012;30(Suppl 1):A179-84. DOI: 10.1016/j.vaccine.2011.08.110 PMID: 22520129

  34. Burns EM, Rigby E, Mamidanna R, Bottle A, Aylin P, Ziprin P,  et al.  Systematic review of discharge coding accuracy. J Public Health (Oxf). 2012;34(1):138-48. DOI: 10.1093/pubmed/fdr054 PMID: 21795302

  35. Ducharme R, Benchimol EI, Deeks SL, Hawken S, Fergusson DA, Wilson K. Validation of diagnostic codes for intussusception and quantification of childhood intussusception incidence in Ontario, Canada: a population-based study.J Pediatr. 2013;163(4):1073-9.e3. DOI: 10.1016/j.jpeds.2013.05.034 PMID: 23809052

  36. Mullooly JP, Donahue JG, DeStefano F, Baggs J, Eriksen E, VSD Data Quality Working Group. Predictive value of ICD-9-CM codes used in vaccine safety research.Methods Inf Med. 2008;47(4):328-35.PMID: 18690366

Back to Table of Contents
Previous Download (pdf)

The publisher’s policy on data collection and use of cookies.

Disclaimer: The opinions expressed by authors contributing to Eurosurveillance do not necessarily reflect the opinions of the European Centre for Disease Prevention and Control (ECDC) or the editorial team or the institutions with which the authors are affiliated. Neither ECDC nor any person acting on behalf of ECDC is responsible for the use that might be made of the information in this journal. The information provided on the Eurosurveillance site is designed to support, not replace, the relationship that exists between a patient/site visitor and his/her physician. Our website does not host any form of commercial advertisement. Except where otherwise stated, all manuscripts published after 1 January 2016 will be published under the Creative Commons Attribution (CC BY) licence. You are free to share and adapt the material, but you must give appropriate credit, provide a link to the licence, and indicate if changes were made. You may do so in any reasonable manner, but not in any way that suggests the licensor endorses you or your use.

Eurosurveillance [ISSN] - ©2007-2016. All rights reserved

This website is certified by Health On the Net Foundation. Click to verify. This site complies with the HONcode standard for trustworthy health information:
verify here.